Plasmin-Loaded Echogenic Liposomes for Ultrasound-Mediated Thrombolysis

Translational Stroke Research

Volumn 6, Issue 1, 2015, Pages 78-87

  Kandadai, Madhuvanthi A ^a   Meunier, Jason M ^a   Hart, Kimberley ^a   Holland, Christy K ^a   Shaw, George J ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Acute ischemic stroke; Echogenic liposomes; Plasmin; Thrombolysis; Ultrasound

Indexed keywords

ALTEPLASE; ECHOGENIC LIPOSOME; LIPOSOME; PLASMIN; UNCLASSIFIED DRUG; FIBRINOLYTIC AGENT;

ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING DISORDER; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; DRUG RELEASE; ECHOGRAPHY; FIBRINOLYTIC THERAPY; HUMAN; IN VITRO STUDY; LIPOSOMAL DELIVERY; MICROBUBBLE; MICROENCAPSULATION; OSCILLATION; PARTICLE SIZE; PHOSPHOLIPID BILAYER; PHOSPHOLIPID VESICLE; PRIORITY JOURNAL; ULTRASOUND SCANNER; ULTRASOUND TRANSDUCER; PROCEDURES; THERAPEUTIC USE; THROMBOSIS; ULTRASOUND;

FIBRINOLYSIN; FIBRINOLYTIC AGENTS; HUMANS; LIPOSOMES; MICROBUBBLES; THROMBOLYTIC THERAPY; THROMBOSIS; ULTRASONICS;

EID: 84925543224     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-014-0376-4     Document Type: Article

References (66)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics 2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28–292. doi:10.1161/01.cir.0000441139.02102.80.
2. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581–8. doi:10.1056/NEJM199512143332401.
3. The ATLANTIS, ECASS, and NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363(9411):768–74. doi:10.1016/s0140-6736(04)15692-4.
4. Burgin WS, Malkoff M, Felberg RA, Demchuk AM, Christou I, Grotta JC, et al. Transcranial doppler ultrasound criteria for recanalization after thrombolysis for middle cerebral artery stroke. Stroke. 2000;31(5):1128–32.
5. Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology. 2002;59(6):862–7.
6. Yepes M, Roussel BD, Ali C, Vivien D. Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic. Trends Neurosci. 2009;32(1):48–55.
7. Kaur J, Zhao Z, Klein GM, Lo EH, Buchan AM. The neurotoxicity of tissue plasminogen activator? J Cereb Blood Flow Metab. 2004;24(9):945–63.
8. Marder VJ, Landskroner K, Novokhatny V, Zimmerman TP, Kong M, Kanouse JJ, et al. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit. Thromb Haemost. 2001;86(3):739–45.
9. Novokhatny V, Taylor K, Zimmerman TP. Thrombolytic potency of acid-stabilized plasmin: superiority over tissue-type plasminogen activator in an in vitro model of catheter-assisted thrombolysis. J Thromb Haemost. 2003;1(5):1034–41.
10. Stewart D, Kong M, Novokhatny V, Jesmok G, Marder VJ. Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage. Blood. 2003;101(8):3002–7. doi:10.1182/blood-2002-08-2546.
11. Marder VJ, Chute DJ, Starkman S, Abolian AM, Kidwell C, Liebeskind D, et al. Analysis of thrombi retrieved from cerebral arteries of patients with acute ischemic stroke. Stroke. 2006;37(8):2086–93. doi:10.1161/01.str.0000230307.03438.94.
12. Shlansky-Goldberg RD, Matsumoto AH, Baumbach GA, Siegel JB, Raabe RD, Murphy TP, et al. A first-in-human phase I trial of locally delivered human plasmin for hemodialysis graft occlusion. J Thromb Haemost. 2008;6(6):944–50. doi:10.1111/j.1538-7836.2008.02969.x.
13. Saver JL, Mitchell P. A Safety and dose finding study of plasmin (Human) administered into the middle cerebral artery of stroke patients. 2009. http://clinicaltrials.gov/show/NCT01014975. Accessed 12 Nov 2014.
14. Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood. 1991;78(12):3114–24.
15. Marder VJ, Novokhatny V. Direct fibrinolytic agents: biochemical attributes, preclinical foundation and clinical potential. J Thromb Haemost. 2010;8(3):433–44.
16. Motoyama H, Chen F, Ohsumi A, Hijiya K, Okita K, Kondo K, et al. Protective effect of plasmin in marginal donor lungs in an ex vivo lung perfusion model. J Heart Lung Transplant. 32(4):S247. doi:10.1016/j.healun.2013.01.637.
17. Marder VJ, Comerota AJ, Shlansky-Goldberg RD, Davis JP, Deng C, Hanna K, et al. Safety of catheter-delivered plasmin in patients with acute lower extremity arterial or bypass graft occlusion: phase I results. J Thromb Haemost. 2012;10(6):985–91. doi:10.1111/j.538-7836.2012.04728.x.
18. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965;13(1):238–52.
19. Holland CK, McPherson DD, editors. Echogenic liposomes for targeted drug delivery. Biomedical Imaging: From Nano to Macro, 2009. ISBI ‘09. IEEE International Symposium on; 2009 June 28 2009-July 1 2009.
20. Alkan-Onyuksel H, Demos SM, Lanza GM, Vonesh MJ, Klegerman ME, Kane BJ, et al. Development of inherently echogenic liposomes as an ultrasonic contrast agent. J Pharm Sci. 1996;85(5):486–90. doi:10.1021/js950407f.
21. Huang S-L, Hamilton AJ, Nagaraj A, Tiukinhoy SD, Klegerman ME, McPherson DD, et al. Improving ultrasound reflectivity and stability of echogenic liposomal dispersions for use as targeted ultrasound contrast agents. J Pharm Sci. 2001;90(12):1917–26. doi:10.1002/jps.1142.
22. Huang S-L, Hamilton AJ, Pozharski E, Nagaraj A, Klegerman ME, McPherson DD, et al. Physical correlates of the ultrasonic reflectivity of lipid dispersions suitable as diagnostic contrast agents. Ultrasound Med Biol. 2002;28(3):339–48. doi:10.1016/s0301-5629(01)00512-9.
23. Gulsen D, Li C-C, Chauhan A. Dispersion of DMPC liposomes in contact lenses for ophthalmic drug delivery. Curr Eye Res. 2005;30(12):1071–80. doi:10.1080/02713680500346633.
24. Klegerman ME, Zou Y, Mcpherson DD. Fibrin targeting of echogenic liposomes with inactivated tissue plasminogen activator. J Liposome Res. 2008;18(2):95–112. doi:10.1080/08982100802118482.
25. Pavelic Z, Skalko-Basnet N, Filipovic-Grçic J, Martinac A, Jalsenjak I. Development and in vitro evaluation of a liposomal vaginal delivery system for acyclovir. J Control Release. 2005;106(1–2):34–43. doi:10.1016/j.jconrel.2005.03.032.
26. Rifai B, Arvanitis CD, Bazan-Peregrino M, Coussios C-C. Cavitation-enhanced delivery of macromolecules into an obstructed vessel. J Acoust Soc Am. 2010;128(5):EL310–5.
27. Andresen TL, Jensen SS, Jorgensen K. Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog Lipid Res. 2005;44(1):68–97. doi:10.1016/j.plipres.2004.12.001.
28. Mamot C, Drummond DC, Hong K, Kirpotin DB, Park JW. Liposome-based approaches to overcome anticancer drug resistance. Drug Resist Updat. 2003;6(5):271–9. doi:10.1016/s1368-7646(03)00082-7.
29. Mayer LD, Krishna R, Webb M, Bally M. Designing liposomal anticancer drug formulations for specific therapeutic applications. J Liposome Res. 2000;10(2-3):99–115. doi:10.3109/08982100009029381.
30. Ramachandran S, Quist AP, Kumar S, Lal R. Cisplatin nanoliposomes for cancer therapy:AFM and fluorescence imaging of cisplatin encapsulation, stability, cellular uptake, and toxicity. Langmuir. 2006;22(19):8156–62. doi:10.1021/la0607499.
31. Sadava D, Coleman A, Kane SE. Liposomal daunorubicin overcomes drug resistance in human breast, ovarian and lung carcinoma cells. J Liposome Res. 2002;12(4):301–9. doi:10.1081/lpr-120016196.
32. Shaw GJ, Meunier JM, Huang S-L, Lindsell CJ, McPherson DD, Holland CK. Ultrasound-enhanced thrombolysis with tPA-loaded echogenic liposomes. Thromb Res. 2009;124(3):306–10. doi:10.1016/j.thromres.2009.01.008.
33. Huang S-L, McPherson DD, MacDonald RC. A method to co-encapsulate gas and drugs in liposomes for ultrasound-controlled drug delivery. Ultrasound Med Biol. 2008;34(8):1272–80. doi:10.1016/j.ultrasmedbio.2008.01.005.
34. Radhakrishnan K, Haworth KJ, Huang S-L, Klegerman ME, McPherson DD, Holland CK. Stability of echogenic liposomes as a blood pool ultrasound contrast agent in a physiologic flow phantom. Ultrasound Med Biol. 2012;38(11):1970–81. doi:10.1016/j.ultrasmedbio.2012.06.012.
35. Porter TM, Smith DA, Holland CK. Acoustic techniques for assessing the Optison destruction threshold. J Ultrasound Med. 2006;25(12):1519–29.
36. Smith DA, Porter TM, Martinez J, Huang S, MacDonald RC, McPherson DD, et al. Destruction thresholds of echogenic liposomes with clinical diagnostic ultrasound. Ultrasound Med Biol. 2007;33(5):797–809. Epub 2007 Apr 6.
37. Kopechek JA, Haworth KJ, Raymond JL, Douglas Mast T, Perrin SR, Klegerman ME, et al. Acoustic characterization of echogenic liposomes: frequency-dependent attenuation and backscatter. J Acoust Soc Am. 2011;130(5):3472–81.
38. Raymond JL, Haworth KJ, Bader KB, Radhakrishnan K, Huang S-L, McPherson DD, et al., editors. Broadband attenuation and size measurements of ultrasound contrast agents. 14th World Congress of Ultrasound in Medicine and Biology; 2013 May 2-5; Sao Paulo, Brasil.
39. Raymond JL, Haworth KJ, Bader KB, Radhakrishnan K, Griffin JK, Huang S-L, et al. Broadband attenuation measurements of phospholipid­shelled ultrasound contrast agents. Ultrasound Med Biol. 2014;40(2):410–21.
40. Kandadai MA, Meunier J, Lindsell CJ, Shaw GJ, Elkind MSV. Short-term high-dose effect of lovastatin on thrombolysis by rt-PA in a human whole-blood in vitro clot model. Curr Neurovasc Res. 2012;9(3):207–13.
41. Meunier JM, Wenker E, Lindsell CJ, Shaw GJ. Individual lytic efficacy of recombinant tissue plasminogen activator in an in-vitro human clot model: rate of “nonresponse”. Acad Emerg Med. 2013;20(5):449–55. doi:10.1111/acem.12133.
42. Shaw GJ, Meunier JM, Lindsell CJ, Pancioli AM, Holland CK. Making the right choice: optimizing rt-PA and eptifibatide lysis, an in vitro study. Thromb Res. 2010;126(4):e305–11. doi:10.1016/j.thromres.2010.07.020.
43. Meunier JM, Holland CK, Lindsell CJ, Shaw GJ. Duty cycle dependence of ultrasound enhanced thrombolysis in a human clot model. Ultrasound Med Biol. 2007;33:576–83.
44. Meunier JM, Smith DAB, Holland CK, Huang S, McPherson DD, Shaw GJ. 120 khz pulsed ultrasound enhanced thrombolysis with tissue plasminogen activator-loaded echogenic liposomes. J Acoust Soc Am. 2007;122:3052.
45. Reid TJ, Snider R, Hartman K, Greilich PE, Carr BA ME. A method for the quantitative assessment od platelet-induced clot retraction and clot strength in fresh and stored platelets. Vox Sang. 1998;75:270–7.
46. Datta S, Coussios C-C, Ammi AY, Mast TD, de Courten-Myers GM, Holland CK. Ultrasound-enhanced thrombolysis using Definity as a cavitation nucleation agent. Ultrasound Med Biol. 2008;34(9):1421–33. doi:10.1016/j.ultrasmedbio.2008.01.016.
47. Holland CK, Vaidya SS, Coussios C-C, Shaw GJ. Thrombolytic effects of 120-kHz and 1-MHz ultrasound and tissue plasminogen activator on porcine whole blood clots. J Acoust Soc Am. 2002;112(5):2370.
48. Laing ST, Moody MR, Kim H, Smulevitz B, Huang S-L, Holland CK, et al. Thrombolytic efficacy of tissue plasminogen activator-loaded echogenic liposomes in a rabbit thrombus model. Thromb Res. 2012;130(4):629–35. doi:10.1016/j.thromres.2011.11.010.
49. Smith DAB, Vaidya SS, Kopechek JA, Huang S-L, Klegerman ME, McPherson DD, et al. Ultrasound-triggered release of recombinant tissue-type plasminogen activator from echogenic liposomes. Ultrasound Med Biol. 2010;36(1):145–57. doi:10.1016/j.ultrasmedbio.2009.08.009.
50. Janardhanan R, Dwivedi G, Hayat S, Senior R. Myocardial contrast echocardiography: a new tool for assessment of myocardial perfusion. Indian Heart J. 2005;57:210–6.
51. Meunier JM, Chang W-TW, Bluett B, Wenker E, Lindsell CJ, Shaw GJ. Temperature affects thrombolytic efficacy using rt-PA and eptifibatide, an in vitro study. Ther Hypothermia Temp Manag. 2012;2(3):112–8.
52. Meunier JM, Holland CK, Pancioli AM, Lindsell CJ, Shaw GJ. Effect of low frequency ultrasound on combined rt-PA and eptifibatide thrombolysis in human clots. Thromb Res. 2009;123(3):528–36. doi:10.1016/j.thromres.2008.05.011.
53. Alexandrov AV, Wojner AW, Grotta JC. CLOTBUST: design of a randomized trial of ultrasound-enhanced thrombolysis for acute ischemic stroke. J Neuroimaging. 2004;14(2):108–12.
54. Molina CA, Ribo M, Rubiera M, Montaner J, Santamarina E, Delgado-Mederos R, et al. Microbubble administration accelerates clot lysis during continuous 2-MHz ultrasound monitoring in stroke patients treated with intravenous tissue plasminogen activator. Stroke. 2006;37(2):425–9. doi:10.1161/01.str.0000199064.94588.39.
55. Molina CA, Barreto AD, Tsivgoulis G, Sierzenski P, Malkoff MD, Rubiera M, et al. Transcranial ultrasound in clinical sonothrombolysis (TUCSON) trial. Ann Neurol. 2009;66(1):28–38. doi:10.1002/ana.21723.
56. Daffertshofer M, Gass A, Ringleb P, Sitzer M, Sliwka U, Els T, et al. Transcranial low-frequency ultrasound-mediated thrombolysis in brain ischemia: increased risk of hemorrhage with combined ultrasound and tissue plasminogen activator: results of a phase II clinical trial. Stroke. 2005;36(7):1441–6. doi:10.1161/01.STR.0000170707.86793.1a.
57. Azuma T, Kawabata K, Umemura S, Ogihara M, Kubota J, Sasaki A, et al. Bubble generation by standing wave in water surrounded by cranium with transcranial ultrasonic beam. J Jpn Appl Phys. 2005;446B:4625–30.
58. Baron C, Aubry JF, Tanter M, Meairs S, Fink M. Simulation of intracra- nial acoustic fields in clinical trials of sonothrombolysis. Ultrasound Med Biol. 2009;35:1148–58.
59. Saguchi T, Onoue H, Urashima M, Ishibashi T, Abe T, Furuhata H. Effective and safe conditions of low-frequency transcranial ultrasonic thrombolysis for acute ischemic stroke. Neurologic and histologic evaluation in a rat middle cerebral artery stroke model. Stroke. 2008;39:1007–11.
60. Wang Z, Moehring MA, Voie AH, Furuhata H. In vitro evaluation of dual mode ultrasonic thrombolysis method for transcranial applica- tion with an occlusive thrombolysis model. Ultrasound Med Biol. 2008;34:96–102.
61. Shimizu J, Fukuda T, Abe T, Ogihara M, Kubota J, Sasaki A, et al. Ultrasound safety with midfrequency transcranial sonothrombolysis: preliminary study on normal macaca monkey brain. Ultrasound Med Biol. 2012;38(6):1040–50. doi:10.1016/j.ultrasmedbio.2012.02.009.
62. Cheng JY, Holland CK, Shaw GJ. In vitro microscopic imaging of rt-PA thrombolysis with 120-KHz ultrasound in a human clot model. J Acoust Soc Am. 2004;115(5):2524.
63. Crumrine RC, Marder VJ, Taylor GM, Lamanna JC, Tsipis CP, Scuderi P, et al. Intra-arterial administration of recombinant tissue-type plasminogen activator (rt-PA) causes more intracranial bleeding than does intravenous rt-PA in a transient rat middle cerebral artery occlusion model. Exp Transl Stroke Med. 2011;3(1):10. doi:10.1186/2040-7378-3-10.
64. Bizjak N, Bajd F, Vidmar J, Blinc A, Perme MP, Marder VJ, et al. Direct microscopic monitoring of initial and dynamic clot lysis using plasmin or rt-PA in an in vitro flow system. Thromb Res. 2014;133(5):908–13. doi:10.1016/j.thromres.2014.02.008. Epub Feb 22.
65. Banbula A, Zimmerman TP, Novokhatny VV. Blood inhibitory capacity toward exogenous plasmin. Blood Coagul Fibrinolysis. 2007;18(3):241–6.
66. Novokhatny V, Rebbeor J, Scuderi P, Petteway S. Acid-stabilized plasmin as a novel direct-acting thrombolytic. Production of plasma proteins for therapeutic use. New York: Wiley; 2013. p. 259–71.